With growing product sales and a bulging, promising pipeline, once-troubled AstraZeneca PLC looks to be on the road to recovery and that 2018 will be a key year for that transition, according to CEO Pascal Soriot.
Presenting the group's fourth-quarter and full-year market update on Feb 2, Soriot told analysts and reporters that 2017 "was indeed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?